Nicotine Dependence Clinical Trial
Official title:
YMCA Exercise Intervention for Smoking Cessation Study
Verified date | September 2020 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cigarette smoking is the leading cause of death and disability in the United States. Although
smoking has declined since 1964, it is still very common among some groups of people. One
such group is persons with emotional symptoms and disorders. There has been little success in
developing treatments for smoking cessation for smokers with affective disturbances.
Recent work suggests that being sensitive to, and less tolerant of, stress is associated with
many problems in daily life. People with high 'stress sensitivity' tend to use avoidant
strategies to cope with their stress, like smoking. Also, people with high levels of stress
sensitivity report stronger beliefs that smoking will reduce negative feelings. They also
report having a harder time quitting and in fact, are less successful at doing so. This
information suggests that stress sensitivity is important to target during smoking cessation
treatment for smokers with affective vulnerabilities.
This clinical trial will evaluate a treatment that integrates exercise to reduce stress
sensitivity among high stress sensitive smokers. It builds directly from our recent work and
we now seek to adapt it to a more a more accessible and sustainable application. Results will
provide important information on the benefit of an integrated intervention that could be used
in the community for smokers at great risk for relapse and who do not benefit from existing
alternative treatments. This study is the first to test an intervention for stress sensitive
smokers and has the potential to help at-risk individuals experience quitting success and,
ultimately, reduce the burden of tobacco-related cancers in Texas.
Status | Completed |
Enrollment | 150 |
Est. completion date | July 6, 2020 |
Est. primary completion date | July 6, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male and female participants ages 18-65 - Willing and able to provide informed consent, attend all study visits and comply with the protocol - Daily smoker for at least one year - Currently smoke an average of at least 5 cigarettes per day - Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale. - Anxiety Sensitivity Index-3 score = 23 (cut-off score to identify high AS individuals) - Sedentary as defined by moderate-intensity exercise less than 3 days/wk for at least 20 minutes each time - Medical clearance to participate in the protocol Exclusion Criteria: - Use of other tobacco products (including e-cigarettes) - A lifetime history of bipolar disorder, schizophrenia, psychosis, or delusional disorders; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation. - Patients with significant suicidal ideation as determined by structured interview or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention. - Body mass index 40. We selected a BMI of 39.9 as the upper limit in order to screen out individuals with Class III obesity who might be more prone to musculoskeletal injuries than individuals with a BMI<40.0). - Current use of any psychotherapy for smoking cessation not provided by the researchers. - Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt, including Chantix, Zyban, and Nicotine Replacement Treatment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas at Austin | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin | Cancer Prevention Research Institute of Texas, YMCA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Smoking Status after Quit Attempt | Change from baseline in point prevalence abstinence (PPA) after quit attempt at week 6 of the protocol. | 6 weeks | |
Primary | Smoking Status 1 Month after Quit Attempt | Change from baseline in point prevalence abstinence (PPA) after quit attempt at week 10 of the protocol. | Week 10 | |
Primary | Smoking Status 2 Months after Quit Attempt | Change from baseline in point prevalence abstinence (PPA) after quit attempt at week 14 of the protocol. | Week 14 | |
Primary | Smoking Status 3 Months after Quit Attempt | Change from baseline in point prevalence abstinence (PPA) after quit attempt at week 18 of the protocol. | Week 18 | |
Primary | Smoking Status 6 Months after Quit Attempt | Change from baseline in point prevalence abstinence (PPA) after quit attempt at week 30 of the protocol. | Week 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A |